Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganitumab + metformin
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of ganitumab, a monoclonal antibody targeting the type I insulin-like growth factor receptor (IGF-1R), and metformin, an oral antidiabetic medication. This combination was investigated primarily in breast cancer clinical trials, with metformin added to counteract ganitumab-induced hyperglycemia. The combination has shown modest activity in clinical trials but has not advanced to phase III studies.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)IGF-1R (Insulin-like growth factor 1 receptor)ND1 (Mitochondrial electron transport chain complex I)OCT (Organic cation transporter family)
Beyond the preview
Go deeper on ganitumab + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganitumab + metformin.